AP Biosciences (ROCO:6945) EV-to-EBIT : -9.05 (As of Jun. 23, 2024)

View and export this data going back to 2023. Start your Free Trial

What is AP Biosciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, AP Biosciences's Enterprise Value is NT$3,059.17 Mil. AP Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-338.09 Mil. Therefore, AP Biosciences's EV-to-EBIT for today is -9.05.

The historical rank and industry rank for AP Biosciences's EV-to-EBIT or its related term are showing as below:

ROCO:6945' s EV-to-EBIT Range Over the Past 10 Years
Min: -17.4 Med: -9.78 Max: -6.77
Current: -9.05

During the past 4 years, the highest EV-to-EBIT of AP Biosciences was -6.77. The lowest was -17.40. And the median was -9.78.

ROCO:6945's EV-to-EBIT is ranked worse than
100% of 438 companies
in the Biotechnology industry
Industry Median: 8.76 vs ROCO:6945: -9.05

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. AP Biosciences's Enterprise Value for the quarter that ended in Dec. 2023 was NT$2,359.32 Mil. AP Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-338.09 Mil. AP Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -14.33%.

AP Biosciences EV-to-EBIT Historical Data

The historical data trend for AP Biosciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AP Biosciences EV-to-EBIT Chart

AP Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-6.98

AP Biosciences Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial			-	-	-	-	-6.98

Competitive Comparison of AP Biosciences's EV-to-EBIT

For the Biotechnology subindustry, AP Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AP Biosciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AP Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where AP Biosciences's EV-to-EBIT falls into.

AP Biosciences EV-to-EBIT Calculation

AP Biosciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	3059.165	/	-338.092
	=	-9.05

AP Biosciences's current Enterprise Value is NT$3,059.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AP Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-338.09 Mil.

AP Biosciences (ROCO:6945) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

AP Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-338.092	/	2359.3188
	=	-14.33 %

AP Biosciences's Enterprise Value for the quarter that ended in Dec. 2023 was NT$2,359.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AP Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-338.09 Mil.

AP Biosciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of AP Biosciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

AP Biosciences (ROCO:6945) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AP Biosciences Inc (ROCO:6945) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3, Park Street, 17th Floor, Taipei, TWN

Website

https://www.apbioinc.com

AP Biosciences Inc is a clinical-stage bispecific antibody new drug research and development company. It has developed a series of antibody and protein lead drugs through a self-designed technology platform for unmet medical needs, focusing on Specific targets associated with diseases to deliver safe, effective and cost-effective medicines.

AP Biosciences (ROCO:6945) Headlines

No Headlines